Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

September 3, 2025

Study Completion Date

December 31, 2025

Conditions
Meniere DiseaseAllergic RhinitisVertigo
Interventions
DRUG

Montelukast

Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.

DRUG

Placebo

Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.

Trial Locations (2)

90057

House Ear Clinic, Los Angeles

House Institute Foundation, Los Angeles

All Listed Sponsors
collaborator

Cures Within Reach

OTHER

lead

House Ear Institute

OTHER